Journal of Affective Disorders
June 4, 2026
Carlton M Kelly, Mathieu Fradet, Catherine Bostian et al.
Psilocybin has demonstrated promise for improving depressive symptoms in treatment-resistant depression, but its effects on anxiety, quality of life, functioning, and posttraumatic stress symptoms are less well studied. This study reports exploratory findings from an open-label trial in Veterans with TRD. Participants received a single 25-mg dose of psilocybin administered with psychological...
Journal of Psychedelic Studies
May 29, 2026
Alex P. Hood, Gary R Elkins
Abstract Background and Aims Psilocybin-assisted psychotherapy (PAP) is a novel, transdiagnostic treatment in which the 5-HT2A receptor agonist psilocybin is combined with psychotherapy. Studies to date have evaluated PAP's effects on depression, substance use, and end-of-life adjustment. Relatively less attention has been given to its effects on anxiety symptoms, which are highly comorbid with...
PsyArXiv
May 14, 2026
Jacob Cohen, Peter Parbo, Per Trads Ørskov et al.
preprint
Background: Social anxiety disorder is a chronic and disabling condition with limited response to standard therapies. Low-dose psilocybin may enhance the effectiveness of exposure-based treatments by modulating neural circuits associated with fear and avoidance. Virtual reality exposure therapy offers a controlled and individualized platform for intervention. Objective: This phase 2b,...
Premier Journal of Neuroscience
May 11, 2026
Khadija Kamene
Background: Treatment-resistant depression (TRD) affects a significant proportion of individuals with major depressive disorder and remains difficult to manage with conventional treatments. Psychedelic-assisted therapies and neuromodulation have emerged as innovative interventions targeting neurobiological mechanisms beyond traditional antidepressant approaches. Objectives: This scoping review...
JOURNAL OF ADVANCE AND FUTURE RESEARCH
May 1, 2026
Gyandev Gupta, Ravina Yadav
Depression is one of the most common mental health challenges people face today. It goes beyond just feeling sad — it shapes the way a person thinks, behaves, and experiences the world around them. The persistent low mood, the fading interest in things that once brought joy, the fog that makes even simple decisions feel overwhelming — all of it quietly chips away at a person's quality of life....
Journal of Pain and Symptom Management
March 27, 2026
Ana Cláudia Mesquita Garcia, Geovanna Maria Isidoro, Cremilson de Paula Silva
CONTEXT: People living with serious illness frequently experience intense existential suffering related to awareness of finitude. Psychedelic-assisted therapies have been associated with reductions in death anxiety and existential distress, yet the experiential processes underlying transformations in the relationship with finitude remain insufficiently understood. OBJECTIVES: To synthesize...
Journal of Psychopharmacology
March 13, 2026
Francisco Moreno, Katja Ehrmann Allen, Christopher B. Wiegand et al.
3 citations
BACKGROUND: Current treatments for obsessive-compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive-behavioral therapy, are often insufficient. Psilocybin, a 5HT2a agonist psychedelic, has shown promise for treating OCD, but rigorous evidence is still needed. AIMS: This randomized clinical trial evaluated safety, tolerability, and benefit of multiple psilocybin doses...
Journal of Innovative and Creativity
March 11, 2026
Agriefa Chrysantia Noormay El Kariim, Novia Tria Nurcahya, Almira Clarissa Sungkono et al.
Background: Cancer patients often experience significant emotional burdens due to the diagnosis, treatment process, and uncertainty regarding their prognosis. Psilocybin, a psychedelic compound found in certain mushroom species, has gained increasing attention in mental health research for its potential therapeutic effects in treating depression and anxiety. Methods: This systematic review...
Therapeutic Advances in Psychopharmacology
March 1, 2026
Ana Deutsch, Luis E. Contreras, Sarah Kratina et al.
Background: Psychedelic therapies are gaining attention as tools to alleviate anxiety and depression across various clinical populations. However, the mechanisms behind psychedelics' therapeutic efficacy and the potential differences in how patients with certain diagnoses experience their subjective effects remain unknown. One commonly suggested mediator of positive outcomes across psychedelics...
Scientific Reports
February 25, 2026
Albert Garcia‐romeu, Gideon P. Naudé, Alison W. Rebman et al.
2 citations
Abstract Lyme disease, caused by the bacterium Borrelia burgdorferi , is the most common vector-borne disease in the United States and Europe. Although antibiotics effectively treat most cases, an estimated 10–20% of patients develop post-treatment Lyme disease (PTLD), a chronic syndrome marked by fatigue, pain, cognitive difficulties, mood disturbance, and reduced quality of life. There are no...